Lorbrena
Named-patient access overview. Lorbrena is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Lorbrena (lorlatinib) is an oral third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor developed by Pfizer. The US Food and Drug Administration approved Lorbrena in November 2018 for ALK-positive metastatic non-small cell lung cancer after disease progression on prior ALK-directed therapy, and in March 2021 in the first-line setting based on the CROWN trial demonstrating improved progression-free survival versus crizotinib. The standard daily dose is 100 mg, given as one 100 mg tablet or four 25 mg tablets.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Lorbrena
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Lorbrena is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Lorbrena in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Lorbrena
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.